Fatty acid oxidation and autophagy promote endoxifen resistance and counter the effect of AKT inhibition in ER-positive breast cancer cells

Tamoxifen (TAM) is the first-line endocrine therapy for estrogen receptor-positive (ER+) breast cancer (BC). However, acquired resistance occurs in ∼50% cases. Meanwhile, although the PI3K/AKT/mTOR pathway is a viable target for treatment of endocrine therapy-refractory patients, complex signaling f...

Descripción completa

Detalles Bibliográficos
Autores principales: Duan, Lei, Calhoun, Sarah, Shim, Daeun, Perez, Ricardo E, Blatter, Lothar A, Maki, Carl G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436705/
https://www.ncbi.nlm.nih.gov/pubmed/33755174
http://dx.doi.org/10.1093/jmcb/mjab018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436705/
https://www.ncbi.nlm.nih.gov/pubmed/33755174
http://dx.doi.org/10.1093/jmcb/mjab018

Ejemplares similares